Johnson, M. L., Riely, G. J., Rizvi, N. A., Azzoli, C. G., Kris, M. G., Sima, C. S., . . . Miller, V. A. (2011). Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib.

Johnson, Melissa L., Greg J. Riely, Naiyer A. Rizvi, Christopher G. Azzoli, Mark G. Kris, Camelia S. Sima, Michelle S. Ginsberg, William Pao, i Vincent A. Miller. Phase II Trial of Dasatinib for Patients With Acquired Resistance to Treatment With the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib. 2011.

Johnson, Melissa L., et al. Phase II Trial of Dasatinib for Patients With Acquired Resistance to Treatment With the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib. 2011.